For Healthcare Professionals

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)

clipboard-pencil

About the study

A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Active subfoveal CNV lesion or juxtafoveal CNV lesion with foveal involvement that is secondary to AMD in the Study Eye.
  2. An ETDRS BCVA score between 60 and 25 (inclusive) letters in the Study Eye.

EXCLUSION CRITERIA

Main Exclusion Criteria:

  1. Any previous treatment for neovascular AMD.
  2. Clinically significant ocular disorders (other than neovascular AMD), which may interfere with assessment of BCVA, assessment of safety, or fundus imaging.
  3. Any current (or history of a) social, psychological, or medical condition that precludes enrolment into the study.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Neovascular Age-related Macular Degeneration

Age (in years)

50+

Phase

Phase 3

Participants needed

990

Est. Completion Date

Dec 31, 2024

Treatment type

Interventional


Sponsor

Opthea Limited

ClinicalTrials.gov identifier

NCT04757610

Study number

OPT-302-1004

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.